FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IV Adult Soft Tissue Sarcoma
Adult Liposarcoma
Adult Synovial Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma

Interventions: Drug: cyclophosphamide
Biological: NY-ESO-1-specific T cells
Other: laboratory biomarker analysis

First Posted Date: 2011-11-22

Last Posted Date: 2014-12-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01477021

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Phase 1

Completed

Conditions: Refractory Chronic Lymphocytic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

Interventions: Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes

First Posted Date: 2011-11-21

Last Posted Date: 2017-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01475058

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Promyelocytic Leukemia (M3)
Adult Erythroleukemia (M6a)
Secondary Acute Myeloid Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: bortezomib

First Posted Date: 2011-11-04

Last Posted Date: 2017-04-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01465386

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2

Terminated

Conditions: Post-Transplant Lymphoproliferative Disorder
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Burkitt Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Radiation: Indium In-111 Ibritumomab Tiuxetan
Drug: Mycophenolate Mofetil
Other: Pharmacological Study
Biological: Rituximab
Radiation: Total-Body Irradiation
Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
Drug: Fludarabine

First Posted Date: 2011-09-15

Last Posted Date: 2021-07-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01434472

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloid Leukemia in Remission
Adult Erythroleukemia (M6a)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Adult Pure Erythroid Leukemia (M6b)
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Blastic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine phosphate
Drug: busulfan
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2011-09-02

Last Posted Date: 2017-05-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01427881

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Diet and Systemic Inflammation

Not Applicable

Completed

Conditions: Intestinal Permeability
Type 2 Diabetes Mellitus
Low-grade Chronic Inflammation
Cardiovascular Disease
Obesity

Interventions: Other: High-fructose corn syrup-sweetened beverages
Other: Fructose-sweetened beverages
Other: Glucose-sweetened beverages

First Posted Date: 2011-08-26

Last Posted Date: 2017-08-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT01424306

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Phase 2

Terminated

Conditions: Recurrent Adult Burkitt Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Anaplastic Large Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Small Intestine Lymphoma
Splenic Marginal Zone Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: lenalidomide
Biological: rituximab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2011-08-18

Last Posted Date: 2017-07-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01419795

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Not Applicable

Completed

Conditions: Vasomotor Disturbance
Hot Flashes
Menopause

Interventions: Drug: Placebo
Drug: Low-dose 17-ß-estradiol with progesterone taper
Drug: Venlafaxine XR

First Posted Date: 2011-08-17

Last Posted Date: 2014-08-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 339

Registration Number: NCT01418209

Locations: 🇺🇸
Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Harvard Medical School (HU), Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania, UP, Philadelphia, Pennsylvania, United States

and more 1 locations

Scleroderma Treatment With Autologous Transplant (STAT) Study

Phase 2

Active, not recruiting

Conditions: Systemic Scleroderma

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Plerixafor
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2011-08-10

Last Posted Date: 2023-11-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01413100

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 9 locations

Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder

Phase 4

Completed

Conditions: Alcohol Use Disorder
HIV

Interventions: Drug: Placebo pill
Drug: oral naltrexone

First Posted Date: 2011-06-21

Last Posted Date: 2017-06-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 159

Registration Number: NCT01377168

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy